scholarly article | Q13442814 |
P356 | DOI | 10.1200/JCO.2008.21.5681 |
P698 | PubMed publication ID | 19414667 |
P50 | author | Morten Høyer | Q61142632 |
P2093 | author name string | Rolf Lewensohn | |
Kristina Nilsson | |||
Giovanna Gagliardi | |||
Jan Nyman | |||
Karl-Axel Johansson | |||
Christer Sederholm | |||
Ingmar Lax | |||
Signe Friesland | |||
Jo-Asmund Lund | |||
Pia Baumann | |||
Lars Ekberg | |||
Merete Paludan | |||
Anders Traberg | |||
Lena Wittgren | |||
Elisabeth Morhed | |||
Nina Levin | |||
Ninni Drugge | |||
Berit Wennberg | |||
P433 | issue | 20 | |
P921 | main subject | lung cancer | Q47912 |
phase II clinical trial | Q42824440 | ||
P304 | page(s) | 3290-3296 | |
P577 | publication date | 2009-05-04 | |
P1433 | published in | Journal of Clinical Oncology | Q400292 |
P1476 | title | Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy | |
P478 | volume | 27 |
Q38428533 | (Radio)biological optimization of external-beam radiotherapy |
Q40271942 | 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. |
Q89904623 | A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients |
Q55071263 | A dosimetric comparison of three-dimensional conformal radiotherapy, volumetric-modulated arc therapy, and dynamic conformal arc therapy in the treatment of non-small cell lung cancer using stereotactic body radiotherapy. |
Q48312990 | A dosimetric parameter to limit chest wall toxicity in SABR of NSCLC. |
Q41825343 | A dosimetric phantom study of dose accuracy and build-up effects using IMRT and RapidArc in stereotactic irradiation of lung tumours |
Q57282826 | A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer |
Q36315106 | A method of dose reconstruction for moving targets compatible with dynamic treatments |
Q32173730 | A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE) |
Q26801050 | A review of stereotactic body radiotherapy - is volumetric modulated arc therapy the answer? |
Q36119520 | A review of update clinical results of carbon ion radiotherapy |
Q93347944 | A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer |
Q38790915 | A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer |
Q29248448 | A treatment-planning comparison of three beam arrangement strategies for stereotactic body radiation therapy for centrally located lung tumors using volumetric-modulated arc therapy |
Q92281611 | Adoption of Stereotactic Body Radiotherapy for Stage IA Non-Small Cell Lung Cancer Across the United States |
Q52723380 | Age-not Charlson Co-morbidity Index-predicts for mortality after stereotactic ablative radiotherapy for medically inoperable stage I non-small cell lung cancer. |
Q35200640 | Alternative to surgery in early stage NSCLC-interventional radiologic approaches |
Q34337294 | American College of Surgeons Oncology Group Z4099/Radiation Therapy Oncology Group 1021: a randomized study of sublobar resection compared with stereotactic body radiotherapy for high-risk stage I non-small cell lung cancer |
Q87410539 | Analysis of biologically equivalent dose of stereotactic body radiotherapy for primary and metastatic lung tumors |
Q64269417 | Anemia is a poor prognostic factor for stage I non-small cell lung cancer (NSCLC) patients treated with Stereotactic Body Radiation Therapy (SBRT) |
Q55251898 | Angiotensin-converting Enzyme Inhibitors Decrease the Incidence of Radiation-induced Pneumonitis Among Lung Cancer Patients: A Systematic Review and Meta-analysis. |
Q26823670 | Are three doses of stereotactic ablative radiotherapy (SABR) more effective than 30 doses of conventional radiotherapy? |
Q31152462 | Associations of Radiomic Data Extracted from Static and Respiratory-Gated CT Scans with Disease Recurrence in Lung Cancer Patients Treated with SBRT |
Q43042909 | CT-guided (125)I brachytherapy on pulmonary metastases after resection of colorectal cancer: A report of six cases |
Q64964699 | Calculating the individualized fraction regime in stereotactic body radiotherapy for non-small cell lung cancer based on uncomplicated tumor control probability function. |
Q36599965 | Carbon ion radiotherapy for oligo-recurrence in the lung |
Q53914428 | Cardiac Dose and Survival After Stereotactic Body Radiotherapy for Early-stage Non-Small-cell Lung Cancer. |
Q27301421 | Challenges in radiobiological modeling: can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data? |
Q28083924 | Challenges in the treatment of early non-small cell lung cancer: what is the standard, what are the challenges and what is the future for radiotherapy? |
Q99240991 | Chest wall toxicity after stereotactic radiation in early lung cancer: a systematic review |
Q38663392 | Clinical Outcomes of 130 Patients with Primary and Secondary Lung Tumors treated with Cyberknife Robotic Stereotactic Body Radiotherapy |
Q53525161 | Clinical characteristics and outcome of pneumothorax after stereotactic body radiotherapy for lung tumors. |
Q35824272 | Clinical outcome of fiducial-less CyberKnife radiosurgery for stage I non-small cell lung cancer |
Q30570350 | Clinical outcome of hypofractionated breath-hold image-guided SABR of primary lung tumors and lung metastases. |
Q59125770 | Clinical outcomes following advanced respiratory motion management (respiratory gating or dynamic tumor tracking) with stereotactic body radiation therapy for stage I non-small-cell lung cancer |
Q47103518 | Clinical outcomes following image-guided stereotactic body radiation for pulmonary oligometastases |
Q49356303 | Clinical outcomes following image-guided stereotactic body radiation for pulmonary oligometastases |
Q37691881 | Clinical outcomes of CyberKnife stereotactic radiosurgery for elderly patients with presumed primary stage I lung cancer |
Q36101987 | Clinical outcomes of stereotactic body radiotherapy for patients with lung tumors in the state of oligo-recurrence |
Q34202715 | Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size |
Q34663557 | Colorectal hepatic metastasis: Evolving therapies |
Q91700135 | Combination of FDG-PET and FMISO-PET as a treatment strategy for patients undergoing early-stage NSCLC stereotactic radiotherapy |
Q44946517 | Commissioning and initial stereotactic ablative radiotherapy experience with Vero |
Q98178313 | Common Error Pathways in CyberKnife™ Radiation Therapy |
Q38685007 | Comparative Analysis of Local Control Prediction Using Different Biophysical Models for Non-Small Cell Lung Cancer Patients Undergoing Stereotactic Body Radiotherapy. |
Q64236584 | Comparing phase- and amplitude-gated volumetric modulated arc therapy for stereotactic body radiation therapy using 3D printed lung phantom |
Q47446694 | Comparison of Single- and Three-fraction Schedules of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-Small-cell Lung Cancer. |
Q90136503 | Comparison of Three Radiobiological Models in Stereotactic Body Radiotherapy for Non-Small Cell Lung Cancer |
Q36382039 | Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis |
Q38914996 | Comparison of the Effectiveness of Radiofrequency Ablation With Stereotactic Body Radiation Therapy in Inoperable Stage I Non-Small Cell Lung Cancer: A Systemic Review and Pooled Analysis. |
Q38240581 | Comparison of therapeutic results from radiofrequency ablation and stereotactic body radiotherapy in solitary lung tumors measuring 5 cm or smaller |
Q42116312 | Cone-beam computed tomography in lung stereotactic ablative radiation therapy: predictive parameters of early response |
Q34331400 | CyberKnife for hilar lung tumors: report of clinical response and toxicity |
Q33698367 | CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment |
Q53083823 | DART-bid: dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily: high local control in early stage (I/II) non-small-cell lung cancer. |
Q37468265 | Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer |
Q41857918 | Diagnosis, staging and treatment of patients with non-small cell lung cancer for the surgeon. |
Q36661346 | Differences in the dose-volume metrics with heterogeneity correction status and its influence on local control in stereotactic body radiation therapy for lung cancer |
Q36100808 | Does early posttreatment surveillance imaging affect subsequent management following stereotactic body radiation therapy for early-stage non-small cell lung cancer? |
Q30421587 | Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer |
Q36279626 | Dosimetric Feasibility of Dose Escalation Using SBRT Boost for Stage III Non-Small Cell Lung Cancer |
Q93185154 | Dosimetric comparison of different algorithms in stereotactic body radiation therapy (SBRT) plan for non-small cell lung cancer (NSCLC) |
Q42150664 | Dosimetric comparison of three-dimensional conformal radiotherapy, intensity modulated radiotherapy, and helical tomotherapy for lung stereotactic body radiotherapy |
Q37789035 | Early detection and screening of lung cancer |
Q64081214 | Editorial on comparison between stereotactic body radiotherapy and surgery in early stage NCSLC by Scotti |
Q47826009 | Effects of collimator angle, couch angle, and starting phase on motion-tracking dynamic conformal arc therapy (4D DCAT). |
Q41909998 | Efficient approach for determining four-dimensional computed tomography-based internal target volume in stereotactic radiotherapy of lung cancer |
Q27015651 | Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice |
Q37645201 | Emerging treatment options in the management of non-small cell lung cancer. |
Q48010740 | Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Nodal Staging of Stereotactic Ablative Body Radiotherapy Patients |
Q37090175 | Establishing stereotactic body radiotherapy with flattening filter free techniques in the treatment of pulmonary lesions - initial experiences from a single institution |
Q58760175 | Evaluation of delivered dose to a moving target by 4D dose reconstruction in gated volumetric modulated arc therapy |
Q41887780 | Evaluation of heterogeneity dose distributions for Stereotactic Radiotherapy (SRT): comparison of commercially available Monte Carlo dose calculation with other algorithms |
Q37670422 | Exploiting sensitization windows of opportunity in hyper and hypo-fractionated radiation therapy |
Q37151785 | Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree |
Q57058757 | Final report of survival and late toxicities in the Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702) |
Q55110451 | Flattening filter-free technique in volumetric modulated arc therapy for lung stereotactic body radiotherapy: A clinical comparison with the flattening filter technique. |
Q47142210 | Heart rate recovery and survival in patients undergoing stereotactic body radiotherapy for treatment of early-stage lung cancer |
Q83182085 | High-dose proton therapy and carbon-ion therapy for stage I nonsmall cell lung cancer |
Q90115551 | Hypofractionated 192Ir source stereotactic ablative brachytherapy with coplanar template assistance in the primary treatment of peripheral lung cancer |
Q90160118 | Hypofractionated carbon-ion radiotherapy for stage I peripheral nonsmall cell lung cancer (GUNMA0701): Prospective phase II study |
Q36840379 | Hypofractionated radiotherapy for medically inoperable stage I non-small cell lung cancer |
Q52716524 | Image-based management of empiric lung stereotactic body radiotherapy (SBRT) without biopsy: Predictors from a 10-year single institution experience. |
Q41773467 | Image-guided radiation therapy: Physician's perspectives |
Q35663626 | Imaging characteristics of local recurrences after stereotactic body radiation therapy for stage I non-small cell lung cancer: Evaluation of mass-like fibrosis |
Q91868558 | Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors |
Q33639144 | Impact of maximum standardized uptake value of non-small cell lung cancer on detecting lymph node involvement in potential stereotactic body radiotherapy candidates |
Q37301068 | Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy |
Q38705654 | Impacts of lung and tumor volumes on lung dosimetry for nonsmall cell lung cancer |
Q47141026 | Institutional experience on the treatment of lung and liver lesions with stereotactic body radiotherapy and Novalis Exactrac Adaptive Gating technique |
Q36621168 | Intensity-modulated stereotactic body radiotherapy for stage I non-small cell lung cancer |
Q38051243 | Is radiofrequency ablation or stereotactic ablative radiotherapy the best treatment for radically treatable primary lung cancer unfit for surgery? |
Q42108214 | Is staging mediastinoscopy necessary before stereotactic body radiotherapy for inoperable early stage lung cancer? |
Q38233871 | Is stereotactic ablative radiotherapy an alternative to surgery in operable stage I non-small cell lung cancer? |
Q41856048 | Late tumor pseudoprogression followed by complete remission after lung stereotactic ablative radiotherapy |
Q38705115 | Limitations of PET/CT in the Detection of Occult N1 Metastasis in Clinical Stage I(T1-2aN0) Non-Small Cell Lung Cancer for Staging Prior to Stereotactic Body Radiotherapy |
Q64997326 | Lobectomy versus stereotactic ablative radiotherapy for medically operable patients with stage IA non-small cell lung cancer: A virtual randomized phase III trial stratified by age. |
Q50862063 | Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. |
Q47149089 | Low and medium doses of hypofractionated stereotactic radiotherapy could be suboptimal for early-stage lung cancer |
Q37698823 | Low incidence of chest wall pain with a risk-adapted lung stereotactic body radiation therapy approach using three or five fractions based on chest wall dosimetry |
Q47098433 | Lung reirradiation with stereotactic body radiotherapy |
Q61815135 | Lung stereotactic body radiotherapy after past ablative therapy: a single institution case series |
Q47102090 | Lung stereotactic body radiotherapy using a coplanar versus a non-coplanar beam technique: a comparison of clinical outcomes |
Q84632256 | Lung-cancer related chest events detected by periodical follow-up CT after stereotactic body radiotherapy for stage I primary lung cancer: retrospective analysis of incidence of lung-cancer related chest events and outcomes of salvage treatment |
Q36235727 | LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective |
Q88149109 | Management of Lung Cancer in the Elderly |
Q48961059 | Matched-pair and propensity score comparisons of outcomes of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery |
Q64099332 | Maximum standardized uptake value at pre-treatment PET in estimating lung cancer progression after stereotactic body radiotherapy |
Q61804649 | Medically inoperable stage I non-small cell lung cancer: best practices and long-term outcomes |
Q36382553 | Monitor unit optimization in stereotactic body radiotherapy for small peripheral non-small cell lung cancer patients |
Q39186802 | Motion management strategies and technical issues associated with stereotactic body radiotherapy of thoracic and upper abdominal tumors: A review from NRG oncology |
Q64080735 | Multiple primary lung cancer: a rising challenge |
Q39369140 | Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy. |
Q33758565 | No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236 |
Q50518699 | No differences in radiological changes after 3D conformal vs VMAT-based stereotactic radiotherapy for early stage non-small cell lung cancer. |
Q36803114 | Non-small cell lung cancer therapy: safety and efficacy in the elderly |
Q35971331 | Non-small cell lung cancer: the challenges of the next decade |
Q37874768 | Non-small-cell lung cancer. |
Q42157461 | Oligometastatic disease, the curative challenge in radiation oncology |
Q35880933 | Outcomes after Stereotactic Body Radiotherapy versus Limited Resection in Older Patients with Early-Stage Lung Cancer. |
Q35592628 | Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer |
Q38907646 | PD-1 Restrains Radiotherapy-Induced Abscopal Effect. |
Q42154657 | Parenchymal and Functional Lung Changes after Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer-Experiences from a Single Institution |
Q64267035 | Pattern of recurrence after CyberKnife stereotactic body radiotherapy for peripheral early non-small cell lung cancer |
Q47651774 | Patterns of Treatment and Outcomes for Definitive Therapy of Early Stage Non-Small Cell Lung Cancer. |
Q38021143 | Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis |
Q48202266 | Phase I study of stereotactic body radiation therapy for centrally located stage IA non-small cell lung cancer (JROSG10-1). |
Q64277127 | Phase II study of compensator-based non-coplanar intensity-modulated radiotherapy for Stage I non-small-cell lung cancer |
Q53112046 | Positron-emission tomography CT to identify local recurrence in stage I lung cancer patients 1 year after stereotactic body radiation therapy. |
Q55128287 | Possibility of chest wall dose reduction using volumetric-modulated arc therapy (VMAT) in radiation-induced rib fracture cases: comparison with stereotactic body radiation therapy (SBRT). |
Q56528378 | Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie? |
Q61804645 | Predictors of pneumonitis-free survival following lung stereotactic body radiation therapy |
Q47110081 | Preliminary comparison of the registration effect of 4D-CBCT and 3D-CBCT in image-guided radiotherapy of Stage IA non-small-cell lung cancer |
Q26851601 | Primary Treatment Options for High-Risk/Medically Inoperable Early Stage NSCLC Patients |
Q87460952 | Primary non-small cell lung cancer in a transplanted lung treated with stereotactic body radiation therapy. A case study |
Q36524133 | Prognostic factors for local control of stage I non-small cell lung cancer in stereotactic radiotherapy: a retrospective analysis |
Q47735759 | Prospective evaluation of anxiety, depression and quality of life in medically inoperable early stage non-small cell lung cancer patients treated with stereotactic ablative radiotherapy. |
Q30416741 | Quality and safety considerations in stereotactic radiosurgery and stereotactic body radiation therapy: Executive summary |
Q47142130 | Quality and safety in stereotactic radiosurgery and stereotactic body radiation therapy: can more be done? |
Q35180568 | Quality of life and symptoms following stereotactic body radiotherapy in early-stage lung cancer patients |
Q92040126 | Questionnaire survey on treatment planning techniques for lung stereotactic body radiotherapy in Japan |
Q37007890 | Radiation therapy for early stage lung cancer |
Q26765355 | Radio(chemo)therapy in locally advanced nonsmall cell lung cancer |
Q36363955 | Radiobiological modeling analysis of the optimal fraction scheme in patients with peripheral non-small cell lung cancer undergoing stereotactic body radiotherapy |
Q37458027 | Radiobiological modeling of two stereotactic body radiotherapy schedules in patients with stage I peripheral non-small cell lung cancer |
Q33787072 | Radiofrequency ablation for early-stage nonsmall cell lung cancer |
Q47095312 | Radiological differential diagnosis between fibrosis and recurrence after stereotactic body radiation therapy (SBRT) in early stage non-small cell lung cancer (NSCLC). |
Q94592974 | Radiotherapy in Lung Cancer: Current and Future Role |
Q57875955 | Radiothérapie en conditions stéréotaxiques des patients inopérables |
Q58804832 | Reirradiation for locoregionally recurrent non-small cell lung cancer |
Q35835107 | Relative clinical effectiveness of carbon ion radiotherapy: theoretical modelling for H&N tumours. |
Q55119541 | Response criteria in solid tumors (PERCIST/RECIST) and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy. |
Q38802618 | Risk factors and management of oligometastatic non-small cell lung cancer |
Q35907834 | Risk of Pneumonitis After Stereotactic Body Radiation Therapy in Patients With Previous Anatomic Lung Resection |
Q37566614 | Robotic stereotactic body radiation therapy for elderly medically inoperable early-stage non-small cell lung cancer |
Q36493928 | SBRT Treatment of Metachronous Small-Cell and Non-Small-Cell Lung Carcinomas in a Patient with Severe COPD. |
Q35200592 | SBRT in operable early stage lung cancer patients. |
Q42384628 | SBRT versus lobectomy in stage I NSCLC: knowns, unknowns and its interpretation |
Q98771302 | Significant Correlation Between Overall Survival and Mean Lung Dose in Lung Stereotactic Body Radiation Therapy (SBRT) |
Q38871523 | Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies |
Q41946577 | Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours |
Q91742496 | Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review |
Q42079167 | Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma |
Q56523398 | Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial |
Q64248763 | Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Lung Nodules: A Single Institution Series |
Q53062109 | Stereotactic Body Radiotherapy Versus Surgery for Medically Operable Stage I Non–Small-Cell Lung Cancer: A Markov Model–Based Decision Analysis |
Q49310050 | Stereotactic Body Radiotherapy for Early-stage Non-small-cell Lung Cancer in Patients 80 Years and Older: A Multi-center Analysis. |
Q36286591 | Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours |
Q41112569 | Stereotactic ablative radiotherapy (SABR) in operable early stage non-small cell lung cancer (NSCLC) patients: challenge to claim being undisputed gold standard |
Q84443095 | Stereotactic ablative radiotherapy for inoperable stage I NSCLC |
Q35667829 | Stereotactic ablative radiotherapy for stage I NSCLC: Recent advances and controversies |
Q37179433 | Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer |
Q41834552 | Stereotactic body radiation therapy (SBRT) for early stage lung cancer delivers clinically significant radiation to the draining lymph nodes |
Q47159050 | Stereotactic body radiation therapy (SBRT) for early stage lung cancer delivers clinically significant radiation to the draining lymph nodes |
Q57172947 | Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advances |
Q42857993 | Stereotactic body radiation therapy as a derivative of stereotactic radiosurgery: clinically independent but with enduring common themes |
Q36550532 | Stereotactic body radiation therapy for a new lung cancer arising after pneumonectomy: dosimetric evaluation and pulmonary toxicity |
Q57177641 | Stereotactic body radiation therapy for lung, spine and oligometastatic disease: current evidence and future directions |
Q34368868 | Stereotactic body radiation therapy for stage I non-small cell lung cancer: a small academic hospital experience |
Q36555959 | Stereotactic body radiation therapy for the treatment of early-stage minimally invasive adenocarcinoma or adenocarcnioma in situ (formerly bronchioloalveolar carcinoma): a patterns of failure analysis. |
Q64096283 | Stereotactic body radiation therapy in early-stage NSCLC: historical review, contemporary evidence and future implications |
Q34859171 | Stereotactic body radiation therapy is effective and safe in patients with early-stage non-small cell lung cancer with low performance status and severe comorbidity |
Q37649474 | Stereotactic body radiation therapy: a novel treatment modality |
Q38560967 | Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients |
Q90481023 | Stereotactic body radiotherapy feasibility for patients with peripheral stage I lung cancer and poor pulmonary function |
Q58788717 | Stereotactic body radiotherapy for central lung tumors: Finding the balance between safety and efficacy in the "no fly" zone |
Q53054421 | Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis. |
Q46159777 | Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis |
Q38155155 | Stereotactic body radiotherapy for early stage lung cancer |
Q35143839 | Stereotactic body radiotherapy for early-stage non-small cell lung cancer: clinical outcomes from a National Patient Registry |
Q89870886 | Stereotactic body radiotherapy for elderly patients (≥ 75 years) with early-stage non-small cell lung cancer |
Q42033188 | Stereotactic body radiotherapy for small lung tumors in the University of Tokyo Hospital |
Q49356651 | Stereotactic body radiotherapy for stage I non-small cell lung cancer |
Q41273661 | Stereotactic body radiotherapy for stage I non-small-cell lung cancer using higher doses for larger tumors: results of the second study. |
Q33813917 | Stereotactic body radiotherapy for very elderly patients (age, greater than or equal to 85 years) with stage I non-small cell lung cancer |
Q93069239 | Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer |
Q82084588 | Stereotactic body radiotherapy using a radiobiology-based regimen for stage I nonsmall cell lung cancer: a multicenter study |
Q36734816 | Stereotactic body radiotherapy using gated radiotherapy with real-time tumor-tracking for stage I non-small cell lung cancer |
Q90591596 | Stereotactic body radiotherapy versus percutaneous local tumor ablation for early-stage non-small cell lung cancer |
Q38175120 | Stereotactic body radiotherapy: a critical review for nonradiation oncologists |
Q28076058 | Stereotactic body radiotherapy: current strategies and future development |
Q35824255 | Stereotactic radiotherapy for early stage non-small cell lung cancer |
Q38367507 | Surgery or stereotactic ablative radiation therapy: how will be treated operable patients with early stage not small cell lung cancer in the next future? |
Q48369218 | Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review. |
Q36644220 | The effect of beam arrangements and the impact of non-coplanar beams on the treatment planning of stereotactic ablative radiation therapy for early stage lung cancer |
Q34366525 | The impact of abdominal compression on outcome in patients treated with stereotactic body radiotherapy for primary lung cancer |
Q47734152 | The impact of technology on the changing practice of lung SBRT. |
Q38224998 | The role of percutaneous image-guided ablation for lung tumors |
Q64120986 | The use of texture-based radiomics CT analysis to predict outcomes in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy |
Q27000405 | Thermal ablation of malignant lung tumors |
Q37066702 | Toward a planning scheme for emission guided radiation therapy (EGRT): FDG based tumor tracking in a metastatic breast cancer patient |
Q36835347 | Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT). |
Q42098921 | Treatment fractionation for stereotactic radiotherapy of lung tumours: a modelling study of the influence of chronic and acute hypoxia on tumour control probability |
Q55350018 | Treatment of Sarcoma Lung Metastases with Stereotactic Body Radiotherapy. |
Q26853124 | Treatment of early stage non-small cell lung cancer: surgery or stereotactic ablative radiotherapy? |
Q58584561 | Treatment-Related Adverse Effects in Lung Cancer Patients after Stereotactic Ablative Radiation Therapy |
Q39015830 | Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models. |
Q43112508 | Use of FDG-PET to guide dose prescription heterogeneity in stereotactic body radiation therapy for lung cancers with volumetric modulated arc therapy: a feasibility study |
Q38084619 | Volume Modulated Arc Therapy (VMAT) for pulmonary Stereotactic Body Radiotherapy (SBRT) in patients with lesions in close approximation to the chest wall |
Q40342856 | What is the current status of Stereotactic body radiotherapy for stage I non-small cell lung cancer? |
Q38172228 | What would be the most appropriate α/β ratio in the setting of stereotactic body radiation therapy for early stage non-small cell lung cancer |
Q92467682 | Which patients benefit most from stereotactic body radiotherapy or surgery in medically operable non-small cell lung cancer? An in-depth look at patient characteristics on both sides of the debate |
Q89921619 | [Minimally Invasive Therapies For Early Stage Non-Small Cell Lung Cancer] |
Search more.